Verastem Beats Q1 Adjusted Loss Estimates, Reports $18.7M Product Revenue
VSTM sits 36% above its 52-week low of $4.01.
Summary
Verastem reported a Q1 adjusted loss of -$0.43 per share, which was narrower than the analyst consensus of -$0.46, indicating a beat on expectations. The company recorded $18.7 million in net product revenue, driven by the first full year of commercial sales for AVMAPKI FAKZYNJA CO-PACK. This strong Q1 revenue is significant, especially when compared to the $30.9 million reported for the entire prior fiscal year, demonstrating robust commercial execution. Furthermore, Verastem extended its cash runway into the first half of 2027, providing crucial financial stability. Traders will likely view these results positively, focusing on the commercial traction and improved financial outlook. Investors should monitor upcoming early data from the TARGET-D 101 trial in 1H 2026 and the topline readout of the RAMP 301 trial in mid-2027 for future catalysts.
At the time of this announcement, VSTM was trading at $5.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.2M. The 52-week trading range was $4.01 to $11.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.